TABLE 1.
List of viral vector–based COVID-19 vaccines under clinical trial (WHO, 2021).
| Vaccine | Route | Phase | Sponsor(s) | Clinical trial ID |
|---|---|---|---|---|
| Nonreplicating viral vector–based vaccine | ||||
| AZD1222 (ChAdOx1-S) | IM | III | University of Oxford | ISRCTN89951424 |
| AstraZeneca | NCT04516746 | |||
| NCT04540393 | ||||
| Serum Institute of India Pvt. Ltd | CTRI/2020/08/027170 | |||
| Adenovirus type 5 vector | IM | III | CanSino Biological Inc | NCT04526990 |
| NPO Petrovax | NCT04540419 | |||
| Gam-COVID-vac | IM | III | Gamaleya Research Institute | NCT04530396 |
| NCT04564716 | ||||
| Ad26.COV-S (JNJ-78436735, Ad26COVS1) | IM | III | Janssen Vaccines and Prevention B.V. | NCT04505722 |
| NCT04614948 | ||||
| hAd5-S-Fusion + N-ETSD | SC | I | ImmunityBio, Inc | NCT04591717 |
| GRAd-COV2 | IM | I | ReiThera Srl | NCT04528641 |
| Ad5-nCoV | IM | I | Institute of Biotechnology, Academy of Military Medical Sciences, PLA China | NCT04552366 |
| VXA-CoV2-1 | Oral | I | Vaxart | NCT04563702 |
| MVA-SARS-2-S | IM | I | University Medical Center Hamburg-Eppendorf | NCT04569383 |
| AdCOVID | IN | Altimmune | NCT04679909 | |
| Replicating viral vector–based vaccine | ||||
| DelNS1-2019-nCoV-RBD-OPT1) | IN | II | Beijing Wantai Biological | ChiCTR2000039715 |
| Pharmacy and Xiamen University | ||||
| IIBR-100 | IM | II | Israel Institute for Biological Research | NCT04608305 |
| V590 | IM | I | Merck Sharp and Dohme | NCT04569786 |
| COVID-19–101 | IM | I | Institute Pasteur | NCT04497298 |
aIM: intramuscular, IN: intranasal, and SC: subcutaneous.